| Feature | Details |
|---|---|
| Product Name | RIFAXIA-550 Tablets |
| Form | Tablets |
| Key Ingredient | Rifaximin 550 mg |
| Core Benefits | Treats hepatic encephalopathy, IBS-D, traveler’s diarrhea |
| Mechanism of Action | Inhibits bacterial RNA synthesis; acts locally in the gastrointestinal tract |
| Support Areas | Liver disease, digestive infections, bowel disorders |
| Recommended Usage | As directed by a physician; commonly twice daily for hepatic use |
| Target Audience | Adults with chronic liver disease or digestive infections |
| Packaging Type | Blister pack |
| Available Pack Sizes | 10x1x10 tablets |
omposition: Rifaximin 550mg Packing: 10X10
Alu-Alu
Description : RIFAXIA-550 Tablets contain
Rifaximin 550 mg, a non-absorbable broad-spectrum antibiotic primarily used to treat
hepatic encephalopathy, irritable bowel syndrome with diarrhea (IBS-D), and traveler’s diarrhea caused by non-invasive E. coli. It works locally in the intestines to reduce harmful bacteria and toxins without affecting systemic immunity. RIFAXIA-550 is well-tolerated, causes minimal resistance, and is ideal for long-term gut-related conditions under medical supervision. It helps improve brain function in liver disease and reduces recurrence of hepatic encephalopathy episodes.
